Given the amount and complexity of information surrounding the the target specific oral anticoagulants a lengthy didactic educational format has the potential to be overwhelming to the reader and difficult to translate and apply to direct patient care. The proposed book will educate clinicians utilizing a series of clinical cases to simultaneously develop the readers' knowledge base, problem-solving skills, and practically apply their new knowledge to a variety of clinical situations. These will be short focused case presentations that provide critical information and pose questions to the…mehr
Given the amount and complexity of information surrounding the the target specific oral anticoagulants a lengthy didactic educational format has the potential to be overwhelming to the reader and difficult to translate and apply to direct patient care. The proposed book will educate clinicians utilizing a series of clinical cases to simultaneously develop the readers' knowledge base, problem-solving skills, and practically apply their new knowledge to a variety of clinical situations. These will be short focused case presentations that provide critical information and pose questions to the reader at key points in the decision making process. The cases will be relevant to what clinicians will encounter not only on a daily basis, but also reflective of scenarios that clinicians will not encounter regularly, but that they will have to act upon (e.g. a bleeding patient, patient scheduled for elective or emergent procedure, patient with changing renal function, patient on drugs that have aplausible yet unstudied drug interaction with a target specific oral anticoagulant etc). Included in the case studies will be evidence-based discussions (with appropriate references) that provide immediate feedback on the different treatment alternatives that were offered. The case studies will be designed to instruct the reader how to select and effectively utilize the most appropriate agent for a given clinical scenario. They will focus on key features of the target specific oral anticoagulants, what they have in common, how they are unique from each other, as well as illustrating the clinical decision process one should take when selecting an agent or managing a patient already receiving one of the target specific oral agents.
Katie Kiser, Pharm.D., BCACP received her Bachelor of Science in Biology from King University in Bristol, Tennessee and her Doctor of Pharmacy from the University of North Carolina School of Pharmacy in Chapel Hill, North Carolina. She completed her postgraduate year-one residency with emphasis in ambulatory care at Moses Cone Health System in Greensboro, North Carolina and her postgraduate year-tworesidency in ambulatory care at the University of North Carolina Hospitals in Chapel Hill, North Carolina. Dr. Kiser is faculty at South College School of Pharmacy in Knoxville, Tennessee and previously taught at the University of Maryland School of Pharmacy in Baltimore, Maryland. Dr. Kiser has over 10 years of clinical and teaching experience in anticoagulation management and is a Board of Pharmaceutical Specialties certified Ambulatory Care Pharmacist. Dr. Kiser has practiced primarily in the outpatient clinical setting and served as the Director of the UHC AntithrombosisClinic in Baltimore, Maryland from 2010 - 2014. Her current clinical practice is at NHC HealthCare in Farragut, Tennessee where she serves as a consultant pharmacist and specializes in oral anticoagulant management in a diverse rehabilitation and long term care population. Dr. Kiser is an Associate Editor and co-founder of iForumRx.org which is an interactive web-based community designed to inform ambulatory care clinicians about high-quality, practice-changing evidence. Dr. Kiser is highly involved with the American College of Clinical Pharmacy and has served in local and national leadership positions She has written chapters in a leading pharmacy textbook and has participated in clinical research and written many peer-reviewed articles on anticoagulation, health literacy, the scholarship of teaching, and other topics.
Inhaltsangabe
Atrial Fibrillation: Basic simple introductory case.- Patient who desires best reduction in ischemic stroke possible.- Elderly patient (e.g. > 80 years old) .- Patient with prior history of GI hemorrhage.- Patient with history of intracranial hemorrhage while on warfarin.- Patient with history of adherence issues who uses pill box.- Patient with stable moderate chronic kidney disease.- Patient with variable renal function.- Patient with concomitant coronary artery disease.- Patient with concomitant history of venous thromboembolism.- Venous Thromboembolism (VTE): Patient with new DVT.- Patient with new PE.- Patient s/p hip replacement.- Patient in ICU in need of DVT prophylaxis.- Patient with VTE and concomitant atherosclerotic disease.- Patient with DVT in ICU with feeding tube.- Patient with moderate chronic kidney disease and VTE.- Patient with recurrent VTE.- Patient with PE who underwent thrombolytic therapy.- Patient s/p knee replacement.- Acute Coronary Syndrome: Patient on a new oral anticoagulant presenting with ACS.- Patient post PCI.- Patient with ACS with additional indication for oral anticoagulant.- Patient with ST segment elevation MI (lytic candidate) on new oral anticoagulant.- Patient with ACS who will be undergoing bypass surgery.- Drug Interactions: CYP 3A4 inhibitors.- PgP inhibitors.- Pharmacodynamic interactions.- Mixed CYP 3A4/PgP inhibitors.- Plausible (but unproven) drug interactions (e.g. cyclosporine) .- Special Populations: Atrial fibrillation ablation.- Mechanical valves.- Coagulopathies.- Pregnancy.- Malignancies.- Perioperative management-minor procedures.- Perioperative management-major procedures.
Atrial Fibrillation: Basic simple introductory case.- Patient who desires best reduction in ischemic stroke possible.- Elderly patient (e.g. > 80 years old) .- Patient with prior history of GI hemorrhage.- Patient with history of intracranial hemorrhage while on warfarin.- Patient with history of adherence issues who uses pill box.- Patient with stable moderate chronic kidney disease.- Patient with variable renal function.- Patient with concomitant coronary artery disease.- Patient with concomitant history of venous thromboembolism.- Venous Thromboembolism (VTE): Patient with new DVT.- Patient with new PE.- Patient s/p hip replacement.- Patient in ICU in need of DVT prophylaxis.- Patient with VTE and concomitant atherosclerotic disease.- Patient with DVT in ICU with feeding tube.- Patient with moderate chronic kidney disease and VTE.- Patient with recurrent VTE.- Patient with PE who underwent thrombolytic therapy.- Patient s/p knee replacement.- Acute Coronary Syndrome: Patient on a new oral anticoagulant presenting with ACS.- Patient post PCI.- Patient with ACS with additional indication for oral anticoagulant.- Patient with ST segment elevation MI (lytic candidate) on new oral anticoagulant.- Patient with ACS who will be undergoing bypass surgery.- Drug Interactions: CYP 3A4 inhibitors.- PgP inhibitors.- Pharmacodynamic interactions.- Mixed CYP 3A4/PgP inhibitors.- Plausible (but unproven) drug interactions (e.g. cyclosporine) .- Special Populations: Atrial fibrillation ablation.- Mechanical valves.- Coagulopathies.- Pregnancy.- Malignancies.- Perioperative management-minor procedures.- Perioperative management-major procedures.
Atrial Fibrillation: Basic simple introductory case.- Patient who desires best reduction in ischemic stroke possible.- Elderly patient (e.g. > 80 years old) .- Patient with prior history of GI hemorrhage.- Patient with history of intracranial hemorrhage while on warfarin.- Patient with history of adherence issues who uses pill box.- Patient with stable moderate chronic kidney disease.- Patient with variable renal function.- Patient with concomitant coronary artery disease.- Patient with concomitant history of venous thromboembolism.- Venous Thromboembolism (VTE): Patient with new DVT.- Patient with new PE.- Patient s/p hip replacement.- Patient in ICU in need of DVT prophylaxis.- Patient with VTE and concomitant atherosclerotic disease.- Patient with DVT in ICU with feeding tube.- Patient with moderate chronic kidney disease and VTE.- Patient with recurrent VTE.- Patient with PE who underwent thrombolytic therapy.- Patient s/p knee replacement.- Acute Coronary Syndrome: Patient on a new oral anticoagulant presenting with ACS.- Patient post PCI.- Patient with ACS with additional indication for oral anticoagulant.- Patient with ST segment elevation MI (lytic candidate) on new oral anticoagulant.- Patient with ACS who will be undergoing bypass surgery.- Drug Interactions: CYP 3A4 inhibitors.- PgP inhibitors.- Pharmacodynamic interactions.- Mixed CYP 3A4/PgP inhibitors.- Plausible (but unproven) drug interactions (e.g. cyclosporine) .- Special Populations: Atrial fibrillation ablation.- Mechanical valves.- Coagulopathies.- Pregnancy.- Malignancies.- Perioperative management-minor procedures.- Perioperative management-major procedures.
Atrial Fibrillation: Basic simple introductory case.- Patient who desires best reduction in ischemic stroke possible.- Elderly patient (e.g. > 80 years old) .- Patient with prior history of GI hemorrhage.- Patient with history of intracranial hemorrhage while on warfarin.- Patient with history of adherence issues who uses pill box.- Patient with stable moderate chronic kidney disease.- Patient with variable renal function.- Patient with concomitant coronary artery disease.- Patient with concomitant history of venous thromboembolism.- Venous Thromboembolism (VTE): Patient with new DVT.- Patient with new PE.- Patient s/p hip replacement.- Patient in ICU in need of DVT prophylaxis.- Patient with VTE and concomitant atherosclerotic disease.- Patient with DVT in ICU with feeding tube.- Patient with moderate chronic kidney disease and VTE.- Patient with recurrent VTE.- Patient with PE who underwent thrombolytic therapy.- Patient s/p knee replacement.- Acute Coronary Syndrome: Patient on a new oral anticoagulant presenting with ACS.- Patient post PCI.- Patient with ACS with additional indication for oral anticoagulant.- Patient with ST segment elevation MI (lytic candidate) on new oral anticoagulant.- Patient with ACS who will be undergoing bypass surgery.- Drug Interactions: CYP 3A4 inhibitors.- PgP inhibitors.- Pharmacodynamic interactions.- Mixed CYP 3A4/PgP inhibitors.- Plausible (but unproven) drug interactions (e.g. cyclosporine) .- Special Populations: Atrial fibrillation ablation.- Mechanical valves.- Coagulopathies.- Pregnancy.- Malignancies.- Perioperative management-minor procedures.- Perioperative management-major procedures.
Rezensionen
"The purpose is to introduce cardiologists to several aspects of anticoagulation therapy, including pharmacotherapy and clinical management. ... This book is intended for practicing cardiologists and cardiology fellows. ... This is a high quality book. It is quite useful for its readability and for its illustrations. Compared to other similar books on this topic, this one is preferable because it is clearly written and highlights key points well." (Daniel Garcia, Doody's Book Reviews, August, 2017)
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
